Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Blood medications
Antiplatelets,anticoagulants, fibrrinolytics, and blood components
| Question | Answer |
|---|---|
| (Oral antiplatelets)The inhibition of prostaglandins observe with aspirin also poses a risk for ? | GI irritation or bleeding |
| Concerns with aspirin use? | potential to trigger bronchoconstriction in a client with asthma, and renal insufficiency, for clients with preexisting renal impairment. |
| discard aspirin if? | It has a strong vinergar-like odor. |
| Clopidogrel | (Plavix) 70mg PO daily. For prophylaxis of MI, thromboembolic stroke and vascular death.slighty more effective than aspirin in treatment of CHD and secondary prevention of MI. |
| Clopidogrel Drug interactions | Use od NSAIDs may increase risk for GI bleeding. |
| Dipyridamole | (Persantine) developed as a coronary artery vasodilator. |
| Dipyridamole Indication | prevention of postsurgicalthromboembolic complications after cardiac valve replacement. |
| Dypyridamole Adverse Effects | hypotension. |
| Dypyridamole drug interaction | Concurrent use of antiplatelets or anticoagulants may increase bleeding risk. |
| Ticlopidine | (Ticlid) decreases the risk of stroke for clients who have had warning of a thrombotic storke or for those who have had a thrombotic stroke. Should be limited to clients who have not respondedto or tolerated other antiplatelet therapy. |
| Ticlopidine | Concurrent use with NSAIDs will increase bleeding. |
| Ticlopidine Nursing Dx | potential complications of hemorrhage neutropenia, thrombocytopenia. |
| Ticlopidine Implementation | monitor the CBC every 2 weeks until the third month of therapy.Monitor more frequently if the neutrophil count is declining or is 30% |
| Glycoprotein IIb/IIIa inhibitors | These IV agents are strong antiplatelets agents reserved for acute coronary events in part because of their higher risk for bleeding. |
| Abciximab | (ReoPro) adjunct therapy to aspirin and heparin for prevention of acute cardiac vessel ischemic complications in clients undergoing percutaneous transluminal coronary angioplasty or atherectomy (PTCA). |
| Abciximab Pharmacokinetics and Adverse effects | binds to platelets and produces its antiplatelet action. Major bleeding and hypotension are adverse effects. |
| Eptifibatide | (Integrilin) platelet activity returning to normal within 4 hrs of discontinuation of the infusion. |
| Tirofiban | aggrastat |
| Agatroban | is a thrombin inhibitor used to treat thromboembolic events in clients with heparin-induced thrombocytopenia. |
| Normal PTT | 21-35 seconds, goal ranges with anticoagulation: 1.5 to 2.5 times the normal lab value. |
| ACT | Bedside procedure |
| Normal PT | 11 to 13 seconds. |
| INR | Target INR for prevention and treatment of most thromboembolic events 2.5 (range 2 to 3). For individuals with recurrent systemic emboli or mechanical heart valves, goal INR may be as high as 3 (range 2.5 to 3.5) |
| Agatroban (Acova) | Prophylaxis or treatment of thromboembolic events in clients with HIT. |
| Heparin (UFH) |
Created by:
dreca2
Popular Pharmacology sets